scholarly journals Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia

Cancer ◽  
2018 ◽  
Vol 124 (10) ◽  
pp. 2151-2160 ◽  
Author(s):  
Hagop M. Kantarjian ◽  
Yun Su ◽  
Elias J. Jabbour ◽  
Helen Bhattacharyya ◽  
Eric Yan ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document